News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
The company increases its efficiency and is able to face the growing demand for its services.
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
The product will be manufactured at Lupin's facility in Nagpur, India.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Subscribe To Our Newsletter & Stay Updated
